Upstate Active Clinical Trials Seeking Participants
Study title
Prospective Study of Rapamycin for the Treatent of SLE (Sytemic Lupus Erythematosus.
IRB number
5658
What is the purpose of the study?
Purpose is to determine the safety and efficacy of rapamycin/sirolimus for treatment of disease manifestations and for normalizing relevant biomarkers of disease activity in patients with SLE; and to prospectively determine the mechanism of action of Rapamune in patients with SLE.
Who is eligible?
SLE patients who satisfy the criteria for a definitive diagnosis and exhibit ongoing disease activity by SLEDAI greater than 4 will be included. Patietns whose disease activity is controlled by administration of corticsteroids, most commonly, 10 mg of prednisone or equivalent dose of another corticosteroid, will also be included. All subjects will be greater than 18 years of age.
What is involved if I participate?
- How long is the study?
40 SLE patients are needed and 40 Healthy Control Subjects. - Is transportation provided or reimbursed?
Yes - Is parking provided or reimbursed?
Yes - What tests and procedures are involved?
Sirolimus levels are checked; routine lab. and non-routine laboratory studies of relevant lupus biomarkers are done. Up to 100 ml of blood is drawn at each visit.
Who is the doctor administering the study?
Andras Perl MD., Ph.D.
Where will the study take place?
UHCC/The Hill Medical Center / UH Pathology Laboratory/ Rheumatology Lab, 8299 Weiskotten Hall
Who can I contact for more information?
- Name: Sara Wierzbicki
- Phone: 315-464-2117
- Email: wierzbis@upstate.edu
- Fax: 315-464-1947
If you are interested in this trial, please contact the study coordinator or investigator noted above.
